When: Price retests 200 SMA ($79.34)

Then: Add position if structural floor holds at 200 SMA

Reduce initial tranche from 50% to 25% and defer entry pending technical confirmation (RSI reclaiming 55 with positive slope, MACD histogram stabilizing, daily close above 10 EMA at $86.18); otherwise stay flat through Q3 earnings in late October

• Forward P/E of 5.7x is consensus-dependent; actual quarterly data shows Q1 26 gross margin at 11.4% declining to 7.6% in Q2 26, contradicting margin recovery thesis
• Q4 25 reported negative gross margin
• If GM earns half the consensus forward estimate, effective P/E rises to approximately 11x on a leveraged cyclical
• Net debt of $107.6 billion against market cap of $76.8 billion; debt exceeds equity
• 28% FCF yield cited as lumpy, not steady-state; quarterly FCF swings: Q2 25 $425M, Q3 25 $955M, Q4 25 $391M, Q1 26 negative $1.8B, Q2 26 $1.1B
• Capex normalized down from $12.5B to approximately $5B, not a margin story but forced investment pullback
• Beta of 1.33 indicates above-average market sensitivity
• Buyback program of $7-9B annualized against $77B market cap creates a bid, not a guaranteed floor
• New Canadian tariffs just imposed; September and October data will be first prints to quantify impact
• Q3 earnings catalyst in late October will combine tariff impact, margin trajectory, and updated buyback pacing
• MACD histogram red for 12+ sessions, deepening from minus 0.04 to minus 0.35
• Price sitting below 10 EMA at $86.18 and below Bollinger middle at $86.68
• Lower highs forming since $90.30 peak: $89.35, then $87.93
• 52-week high of $91.85 on July 28; current price at $85.50
• Bearish resolution target: test of 50 SMA at $82.73, then 200 SMA at $79.34
• Proposed stop at $78.50 represents $7 per share risk per position
• In recession scenario, this leveraged cyclical historically gets cut in half
• Conservative entry conditions: RSI reclaiming 55 with positive slope, MACD histogram stabilizing, price closing above $86.18
• Bearish confirmation trigger: daily close below 50 SMA at $82.73 on expanding volume
• Bearish target zone: $79.34 or $76-78 prior consolidation

→ vs aggressive: Forward P/E of 5.7x is not a free lunch; consensus assumes margins recover to levels recent data contradicts, with Q1 26 GM at 11.4% and Q2 26 at 7.6% versus Q4 25 negative GM

→ vs aggressive: 28% FCF yield is lumpy and capex-driven, not steady-state; Q2 25 $425M, Q3 25 $955M, Q4 25 $391M, Q1 26 negative $1.8B, Q2 26 $1.1B; capex normalization from $12.5B to ~$5B is forced, not disciplined

→ vs aggressive: Coiled spring thesis lacks momentum confirmation; ATR compression dictates a move is coming, not direction; MACD histogram red for 12+ sessions, price below 10 EMA and Bollinger middle, lower highs since $90.30

→ vs aggressive: Buyback floor argument is flawed; buybacks are discretionary, $7-9B against $77B market cap is meaningful but not a guarantee, and deleveraging cannot proceed at full pace simultaneously

→ vs aggressive: Tariff argument is a low bar; less exposed than Japanese competitors still means exposure, and new Canadian tariffs have not yet shown in quarterly data

→ vs aggressive: Stop at $78.50 sits below structural support and tends to get run over; a closing-basis stop below 50 SMA would allow earlier reaction

→ vs aggressive: 50% initial tranche with leveraged cyclical profile (net debt $107.6B vs market cap $76.8B, beta 1.33) in front of binary catalyst compounds tail risk, not asymmetric opportunity

→ vs neutral: Passive HOLD approach ignores actionable risk management; waiting for technical confirmation rather than simply sitting flat provides discipline without abandoning the ability to participate

Buy thesis with reduced initial tranche of ~30% of target allocation at $85-$86; remaining 70% tranched at 50 SMA (~$82.73) and 200 SMA (~$79.34) on confirmation. Stop on initial position: closing basis below 50 SMA at $82.73 (~$3 risk per share). Full positioning target: before late October Q3 earnings binary.

• Forward earnings consensus of $14.85/share assumes margin recovery not demonstrated in last four quarters: Q4 2025 gross margin was negative, Q2 2026 was 7.6%, Q1 2026 was 11.4%
• 28% FCF yield depends on capex staying at normalized $5 billion level vs potential spike to $12 billion; no contractual assurance of capex discipline
• ATR compression signals a move is coming but not direction; dominant trend is up long-term but sideways-to-down on six-week basis with lower highs and deepening MACD histogram
• 9.2% share count reduction from buybacks is the single strongest bull case element
• Structural uptrend intact: 200 SMA rose from $74.55 to $79.34 in four months; price still above both 50 SMA and 200 SMA
• Net debt of $107.6 billion against $76.8 billion market cap is a genuine concern; beta of 1.33 means amplified market moves in both directions
• Conservative analyst's 8% recession probability is non-zero; historically GM gets cut in half in recessions
• 30% initial tranche allows participation in upward resolution without overexposure to downward resolution
• Tighter stop at $3 risk per share ($82.73) is more responsive than original $7 risk ($78.50) while respecting technical levels
• Buying at 5.7x forward earnings on a dominant franchise is reasonable but represents the optimistic end of a range, not the base case

→ vs aggressive: Treats 5.7x forward P/E and 28% FCF yield as 'free options' when they are contingent claims dependent on assumptions the trend line actively contradicts

→ vs aggressive: Coiled spring/ATR argument conflates signal (direction uncertain); long-term trend up vs short-term sideways-to-down presents ~60%/40% historical resolution probability—not asymmetric

→ vs aggressive: Pricing in the most capital-return-friendly scenario (maximum buybacks plus deleveraging) as the base case when it is actually the bull case

→ vs aggressive: Price is below 10 EMA at $86.18 and below Bollinger middle at $86.68; fighting the chart rather than trading with it

→ vs conservative: Pure HOLD recommendation ignores that structural trend is still up with rising 200 SMA and 50 SMA; waiting for full confirmation risks chasing from ~$90

→ vs conservative: Stop suggestion below 50 SMA at $82.73 contradicts the structural support thesis being defended; gives up the thesis at the precise level that should confirm it

→ vs conservative: Tighter stop at $82.73 ($3 risk) is actually superior to $78.50 ($7 risk) for the initial tranche, yet conservative analyst advocates waiting entirely instead of repositioning